Mink Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Mink Therapeutics

10/05/2024 15:11

* Mink Therapeutics Inc  INKT.OQ   INKT.O  is expected
to show no
change in quarterly revenue when it reports  results on May 14
for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Mink Therapeutics Inc is
for a
loss of 15 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mink
Therapeutics
Inc is $8.00​, above​ its last closing price of $0.90. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023              -0.15      -0.16     Missed  -4.3
 Jan. 1 2023   -0.18       -0.18      -0.15     Beat    17.8
 Jun. 30 2023  -0.19       -0.20      -0.18     Beat    8.9​
 Mar. 31 2023  -0.25       -0.24      -0.17     Beat    28.4
 ​​Dec.                    -0.21      -0.23     Missed  -9.5
 31 2022                                                
 Sep. 30 2022  -0.23       -0.23      -0.19     Beat    18.3​
 Jan. 1 0001   -0.24       -0.24      -0.18     Beat    25
 Mar. 31 2022  -0.21       -0.21      -0.23     Missed  -11.3
 This summary was machine generated May 10 at 14:10 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)